These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 17395698)

  • 1. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton.
    Baron R; Rawadi G
    Endocrinology; 2007 Jun; 148(6):2635-43. PubMed ID: 17395698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt signaling: a key regulator of bone mass.
    Baron R; Rawadi G; Roman-Roman S
    Curr Top Dev Biol; 2006; 76():103-27. PubMed ID: 17118265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt signaling as a therapeutic target for bone diseases.
    Hoeppner LH; Secreto FJ; Westendorf JJ
    Expert Opin Ther Targets; 2009 Apr; 13(4):485-96. PubMed ID: 19335070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo analysis of Wnt signaling in bone.
    Glass DA; Karsenty G
    Endocrinology; 2007 Jun; 148(6):2630-4. PubMed ID: 17395705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt signaling and osteoblastogenesis.
    Bodine PV; Komm BS
    Rev Endocr Metab Disord; 2006 Jun; 7(1-2):33-9. PubMed ID: 16960757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
    Semënov M; Tamai K; He X
    J Biol Chem; 2005 Jul; 280(29):26770-5. PubMed ID: 15908424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the Wnt signaling pathway in osteoblast commitment and differentiation.
    Yavropoulou MP; Yovos JG
    Hormones (Athens); 2007; 6(4):279-94. PubMed ID: 18055419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.
    Williams BO; Insogna KL
    J Bone Miner Res; 2009 Feb; 24(2):171-8. PubMed ID: 19072724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway.
    Glass DA; Karsenty G
    Curr Top Dev Biol; 2006; 73():43-84. PubMed ID: 16782455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Wnt-beta-catenin signaling in bone metabolism].
    Urano T
    Clin Calcium; 2006 Jan; 16(1):54-60. PubMed ID: 16397351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
    Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
    J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.
    Lu W; Liu CC; Thottassery JV; Bu G; Li Y
    Biochemistry; 2010 Jun; 49(22):4635-43. PubMed ID: 20446724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization.
    Chen Y; Hu Y; Lu K; Flannery JG; Ma JX
    J Biol Chem; 2007 Nov; 282(47):34420-8. PubMed ID: 17890782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
    ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
    J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Regulation of bone metabolism by pathogenic mutations and polymorphism in the LRP5-Wnt signaling genes].
    Urano T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():95-100. PubMed ID: 18161089
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cytokines in bone diseases. Wnt signal and excessive bone formation].
    Hosoi T
    Clin Calcium; 2010 Oct; 20(10):1526-31. PubMed ID: 20890035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytokines in bone diseases. Wnt signaling and osteoporosis-pseudoglioma syndrome].
    Ozono K
    Clin Calcium; 2010 Oct; 20(10):1520-5. PubMed ID: 20890034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Wnt signaling and glucocorticoid-induced osteoporosis].
    Ohnaka K
    Clin Calcium; 2006 Nov; 16(11):1812-6. PubMed ID: 17079847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
    Levasseur R; Lacombe D; de Vernejoul MC
    Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.